221 related articles for article (PubMed ID: 14641308)
1. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus.
Yeh RW; Gerson LB; Triadafilopoulos G
Dis Esophagus; 2003; 16(3):193-8. PubMed ID: 14641308
[TBL] [Abstract][Full Text] [Related]
2. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).
Milkes D; Gerson LB; Triadafilopoulos G
Am J Gastroenterol; 2004 Jun; 99(6):991-6. PubMed ID: 15180715
[TBL] [Abstract][Full Text] [Related]
3. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Ouatu-Lascar R; Triadafilopoulos G
Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
[TBL] [Abstract][Full Text] [Related]
4. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.
Spechler SJ; Sharma P; Traxler B; Levine D; Falk GW
Am J Gastroenterol; 2006 Sep; 101(9):1964-71. PubMed ID: 16848802
[TBL] [Abstract][Full Text] [Related]
5. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
6. Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy.
Hatlebakk JG; Zerbib F; Bruley des Varannes S; Attwood SE; Ell C; Fiocca R; Galmiche JP; Eklund S; Långström G; Lind T; Lundell LR;
Clin Gastroenterol Hepatol; 2016 May; 14(5):678-85.e3. PubMed ID: 26226096
[TBL] [Abstract][Full Text] [Related]
7. Review article: is stringent control of gastric pH useful and practical in GERD?
Kahrilas PJ
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
[TBL] [Abstract][Full Text] [Related]
8. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
9. Dual Ambulatory pH Monitoring in Patients with Gastroesophageal Reflux Rendered Asymptomatic with Proton Pump Inhibitor Therapy.
Lin D; Triadafilopoulos G
Dig Dis Sci; 2015 May; 60(5):1343-9. PubMed ID: 25135815
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26422094
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26121346
[TBL] [Abstract][Full Text] [Related]
12. [Gastroesophageal reflux disease refractory to esomeprazole].
Velasco MJ; Ortiz V; Ponce J
Gastroenterol Hepatol; 2005 Feb; 28(2):65-7. PubMed ID: 15710084
[TBL] [Abstract][Full Text] [Related]
13. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
Spechler SJ; Barker PN; Silberg DG
Aliment Pharmacol Ther; 2009 Jul; 30(2):138-45. PubMed ID: 19438416
[TBL] [Abstract][Full Text] [Related]
15. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
[TBL] [Abstract][Full Text] [Related]
16. Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus.
Yachimski P; Maqbool S; Bhat YM; Richter JE; Falk GW; Vaezi MF
Am J Gastroenterol; 2015 Aug; 110(8):1143-8. PubMed ID: 26032153
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of surgical patients with gastroesophageal reflux disease and Barrett's esophagus].
Zsolt S; Paszt A; Géczi T; Abrahám S; Tóth I; Horváth Z; Pieler J; Tajti J; Varga A; Tiszlavicz L; Németh I; Izbéki F; Rosztóczy A; Wittmann T; Lázár G
Magy Seb; 2014 Oct; 67(5):287-96. PubMed ID: 25327403
[TBL] [Abstract][Full Text] [Related]
18. Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.
Baldaque-Silva F; Vieth M; Debel M; Håkanson B; Thorell A; Lunet N; Song H; Mascarenhas-Saraiva M; Pereira G; Lundell L; Marschall HU
World J Gastroenterol; 2017 May; 23(17):3174-3183. PubMed ID: 28533674
[TBL] [Abstract][Full Text] [Related]
19. Symptoms, acid exposure and motility in patients with Barrett's esophagus.
Brandt MG; Darling GE; Miller L
Can J Surg; 2004 Feb; 47(1):47-51. PubMed ID: 14997925
[TBL] [Abstract][Full Text] [Related]
20. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
